Concepedia

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

Jaafar Bennouna, István Láng, Manuel Valladares‐Ayerbes, Katalin Boér, Antoine Adenis, P. Escudero, Tae You Kim, G. Pover, Clive Morris, Jean-Yves Douillard

Investigational New Drugs · 2010 · 139 citations · 13 references

DOIFull text

Open access

Concepts

References

13

Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

Scott Kopetz, George J. Chang, Michael J. Overman et al. · Journal of Clinical Oncology · 2009 · 1.4K citations · Full text

, , +15

Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

Chris Twelves, A. Wong, Marek P. Nowacki et al. · New England Journal of Medicine · 2005 · 1.2K citations · Full text

, , +17

Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study

Paulo M. Hoff, Rafat Ansari, Gerald Batist et al. · Journal of Clinical Oncology · 2001 · 1.1K citations

, , +14

Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study

Eric Van Cutsem, Chris Twelves, Jim Cassidy et al. · Journal of Clinical Oncology · 2001 · 1K citations

, , +14

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Tammie C. Yeh, Vivienne Marsh, Bryan A. Bernat et al. · Clinical Cancer Research · 2007 · 583 citations · Full text

, , +14